Extension usage examples:
Here's how our browser extension sees the article:
Article summary:
1. Immune checkpoint inhibitors (ICIs) have demonstrated durable antitumor effects in treatment of multiple cancer types, but only a subset of patients benefit from such therapies.
2. Currently, only PD-L1 is validated to predict response to ICIs, but it is an imperfect biomarker due to tumour intrinsic PD-L1 heterogeneity and its lability during cancer history.
3. Tumour mutational burden (TMB) has emerged as a promising biomarker for predicting response to ICIs, as it is associated with increased neoantigen production and improved immune response.
Article analysis:
The article “Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts” provides an overview of the current state of research on the use of tumour mutational burden (TMB) as a predictive biomarker for immunotherapy. The article presents the evidence that supports the use of TMB as a predictive biomarker, including its association with increased neoantigen production and improved immune response. However, there are some potential biases in the article that should be noted.
First, the article does not provide any information on possible risks associated with using TMB as a predictive biomarker for immunotherapy. While it is true that TMB may be associated with improved immune response, there is also potential risk that this could lead to hyperprogression or worse prognosis in some patients. This risk should be discussed in order to provide a balanced view of the potential benefits and risks associated with using TMB as a predictive biomarker for immunotherapy.
Second, while the article does discuss other approaches such as transcriptomic signatures or tumour infiltrate lymphocytes (TILs), it does not explore any counterarguments or alternative perspectives on these approaches. For example, while CD8+ T lymphocytes infiltration analysis may improve PD-L1 ability to predict progression-free survival (PFS), there may be other factors at play that could affect PFS which are not discussed in the article.
Finally, while the article does present evidence supporting the use of TMB as a predictive biomarker for immunotherapy, it does not present any evidence against its use or explore any unexplored counterarguments or missing points of consideration which could potentially weaken its reliability and trustworthiness as a predictive marker.
In conclusion, while this article provides an overview of current research on using TMB as a predictive biomarker for immunotherapy and presents evidence supporting its use, there are some potential biases which should be noted when evaluating its trustworthiness and reliability.